Literature DB >> 14747567

Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Josephine M McAuliffe1, Sonja R Surman, Jason T Newman, Jeffrey M Riggs, Peter L Collins, Brian R Murphy, Mario H Skiadopoulos.   

Abstract

The Y942H and L992F temperature-sensitive (ts) and attenuating amino acid substitution mutations, previously identified in the L polymerase of the HPIV3cp45 vaccine candidate, were introduced into homologous positions of the L polymerase of recombinant human parainfluenza virus type 1 (rHPIV1). In rHPIV1, the Y942H mutation specified the ts phenotype in vitro and the attenuation (att) phenotype in hamsters, whereas the L992F mutation specified neither phenotype. Each of these codon mutations was generated by a single nucleotide substitution and therefore had the potential to readily revert to a codon specifying the wild-type amino acid residue. We introduced alternative amino acid assignments at codon 942 or 992 as a strategy to increase genetic stability and to generate mutants that exhibit a range of attenuation. Twenty-three recombinants with codon substitutions at position 942 or 992 of the L protein were viable. One highly ts and att mutant, the Y942A virus, which had a difference of three nucleotides from the codon encoding a wild-type tyrosine, also possessed a high level of genetic and phenotypic stability upon serial passage in vitro at restrictive temperatures compared to that of the parent Y942H virus, which possessed a single nucleotide substitution. We obtained mutants with substitutions at position 992 that, in contrast to the L992F virus, possessed the ts and att phenotypes. These findings identify the use of alternative codon substitution mutations as a method that can be used to generate candidate vaccine viruses with increased genetic stability and/or a modified level of attenuation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747567      PMCID: PMC369445          DOI: 10.1128/jvi.78.4.2029-2036.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

Review 1.  Respiratory syncytial virus: reverse genetics and vaccine strategies.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Virology       Date:  2002-05-10       Impact factor: 3.616

Review 2.  Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

Authors:  Brian R Murphy; Peter L Collins
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Further characterization of the complementation group B temperature-sensitive mutant of respiratory syncytial virus.

Authors:  R B Belshe; L S Richardson; T J Schnitzer; D A Prevar; E Camargo; R M Chanock
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

4.  Isolation and characterization of further defective clones of a temperature sensitive mutant (ts-1) of respiratory syncytial virus.

Authors:  L S Richardson; T J Schnitzer; R B Belshe; E Camargo; D A Prevar; R M Chanock
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

5.  Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States.

Authors:  M E Counihan; D K Shay; R C Holman; S A Lowther; L J Anderson
Journal:  Pediatr Infect Dis J       Date:  2001-07       Impact factor: 2.129

6.  Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population.

Authors:  K J Cortez; D D Erdman; T C Peret; V J Gill; R Childs; A J Barrett; J E Bennett
Journal:  J Infect Dis       Date:  2001-10-12       Impact factor: 5.226

7.  Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo.

Authors:  M D Tolpin; J G Massicot; M G Mullinix; H W Kim; R H Parrott; R M Chanock; B R Murphy
Journal:  Virology       Date:  1981-07-30       Impact factor: 3.616

8.  A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion.

Authors:  F W Henderson; A M Collier; M A Sanyal; J M Watkins; D L Fairclough; W A Clyde; F W Denny
Journal:  N Engl J Med       Date:  1982-06-10       Impact factor: 91.245

9.  The amino-terminal extensions of the longer Sendai virus C proteins modulate pY701-Stat1 and bulk Stat1 levels independently of interferon signaling.

Authors:  Dominique Garcin; Jean-Baptiste Marq; Stephen Goodbourn; Daniel Kolakofsky
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.

Authors:  Mario H Skiadopoulos; Alexander C Schmidt; Jeffrey M Riggs; Sonja R Surman; William R Elkins; Marisa St Claire; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  18 in total

Review 1.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

4.  Genomic features of attenuated Junín virus vaccine strain candidate.

Authors:  Sandra Elizabeth Goñi; Javier Alonso Iserte; Ana Maria Ambrosio; Victor Romanowski; Pablo Daniel Ghiringhelli; Mario Enrique Lozano
Journal:  Virus Genes       Date:  2006-02       Impact factor: 2.332

5.  Rescue of codon-pair deoptimized respiratory syncytial virus by the emergence of genomes with very large internal deletions that complemented replication.

Authors:  Cyril Le Nouën; Thomas McCarty; Lijuan Yang; Michael Brown; Eckard Wimmer; Peter L Collins; Ursula J Buchholz
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

6.  The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Authors:  Ruth A Karron; Roberta Casey; Bhagvanji Thumar; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

Review 7.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

8.  Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.

Authors:  Natalie Mackow; Emérito Amaro-Carambot; Bo Liang; Sonja Surman; Matthias Lingemann; Lijuan Yang; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

9.  Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.

Authors:  Emmalene J Bartlett; Margaret Hennessey; Mario H Skiadopoulos; Alexander C Schmidt; Peter L Collins; Brian R Murphy; Raymond J Pickles
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

10.  Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.